It’s about the vaccinewith the name pvccs Scientist, which is being developed to specifically counter Malaria, produced by the parasite the mosquito Plasmodium vivax, prevalent in America and of course in Colombia.
This vaccine has already passed phases one and part of phase two of clinical trials evidencing a 60% efficiency, the remaining study will be done and will start, at the end of this year, in about 100 volunteers in the department of collidedsince it is the territory that, at least this year, concentrates the greater amount of patients for this disease 5.652, that is, 32% of the national total.
“We seek test the vaccine in people who have already had Malaria and that is why we will do the study in Chocó, which is the Department with the largest record of this illness in the country. What do we expect? That the results already obtained in this first trial are reproducible and desirable improvable. That to the extent that people already had contact in that territory with this disease and with something advanced immunity this can reinforce it and improve the levels”, he affirmed Socrates Herrera immunologist and researcher.
Likewise, Dr. Herrera revealed to Radius Snail that this vaccine is 3 doses, with intervals of 2 to 4 monthstime after which the immunized volunteers would be taken to submit them to the infection deliberately, to show that it does protect. The results of the phase starts at the end this year they would be for mid 2023.
–
